$CANLF - Cannabis Technologies (CTI) is an innovat

$CANLF - Cannabis Technologies (CTI) is an innovative biopharmaceutical company that specializes in developing cannabis-based botanical and non-botanical therapies through the Research and Development into the extensive pharmacology of Cannabinoids dedicated to develop novel medicines, with special focus on drug delivery technologies to improve the quality of life of patients.

CTI is utilizing its proprietary "Cannabinoid Drug Design Platform in conjunction to Molecular Breeding & Genetic techniques" to identify new bioactive compounds within the cannabis plant that interact with certain gene responsible for specific diseases. 

The company consists of two distinct divisions:

• Molecular Breeding & Cultivation - Botanical research division has begun the research & development into the individual strains and clones that will produce the raw material bases for future pharmaceutical research. To comply with the demands of the Pharmaceutical industry, a phytopharmaceutical feedstock must meet high expectations regarding the minimum and maximum content of a range of compounds. Our aim is to use advanced cultivation and breeding techniques and pharmaceutical levels of extracting chemical consistency which are critical for all health applications and for regulatory authorities.

• Drug Discovery & Development - CTI is utilizing its proprietary platform to identify new bioactive compounds within the medicinal plants that interact with certain gene responsible for specific diseases. CTI"s extensive research and intellectual properties will initially be focused on the development of several new plant based treatments for Glaucoma, Cancer & Angiogenesis, Inflammation and Pain.